Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EUTRON vs ALDORIL 15
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
EUTRON is a combination of hydrochlorothiazide (thiazide diuretic) and pargyline (monoamine oxidase inhibitor, MAOI). Hydrochlorothiazide inhibits sodium reabsorption in distal convoluted tubule, reducing plasma volume. Pargyline inhibits MAO, increasing catecholamine levels centrally, leading to antihypertensive effect.
Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
Hypertension
Hypertension
Oral: 5 mg/2.5 mg (amiodipine/valsartan) once daily; maximum dose 10 mg/320 mg once daily.
1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.
Terminal elimination half-life is 12-15 hours in patients with normal renal function. In end-stage renal disease (ESRD), half-life may extend to 24-30 hours, requiring dose adjustment.
Terminal half-life: 12–17 hours; clinical context: steady-state achieved within 2–3 days; effect persists 12–24 hours
Hydrochlorothiazide: primarily excreted unchanged in urine. Pargyline: metabolized via MAO (its target) and other pathways; metabolites excreted renally.
Methyldopa is metabolized in the liver via conjugation and O-methylation; active metabolites include methyldopamine and methylnorepinephrine. Hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Renal excretion accounts for approximately 90% of elimination, with 70% as unchanged drug and 20% as metabolites. Biliary/fecal excretion accounts for the remaining 10%.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
Approximately 95% bound to albumin.
~90%, primarily to albumin
0.3 L/kg, indicating distribution primarily in extracellular fluid. Higher Vd in heart failure (0.5 L/kg) due to increased tissue perfusion.
2–4 L/kg; clinical meaning: extensive tissue distribution, concentrating in vascular smooth muscle
Oral: 60-70% due to first-pass metabolism; significantly reduced by food (decrease by 30%).
Oral: 50–60% (extensive first-pass metabolism)
e GFR ≥30 m L/min/1.73 m²: No adjustment. e GFR <30 m L/min/1.73 m²: Contraindicated due to valsartan component.
GFR 30-50 m L/min: maximum 1 tablet twice daily. GFR <30 m L/min: avoid use.
Child-Pugh A: No adjustment. Child-Pugh B: Use caution; maximum amiodipine dose 5 mg daily. Child-Pugh C: Not recommended.
Child-Pugh A: caution, reduce dose. Child-Pugh B: avoid. Child-Pugh C: contraindicated.
Not established for patients <18 years.
Not recommended for pediatric use; safety in children under 12 years not established.
Initiate at lowest dose (5 mg/2.5 mg once daily) due to increased sensitivity and reduced hepatic/renal function.
Start with 1 tablet once daily; monitor for hypotension and electrolyte imbalance. Reduce initial dose by 50%.
This drug is no longer approved by FDA. Historical black box warning: Pargyline may cause hypertensive crisis when used with certain foods (tyramine-rich) or drugs.
None
Hypertensive crisis due to dietary tyramine or sympathomimetic drugs,Orthostatic hypotension,Electrolyte imbalance from thiazide,Renal impairment,Hepatic encephalopathy
Sedation, usually transient; may impair ability to drive or operate heavy machinery.,Positive Coombs test with hemolytic anemia (rare); monitor hematocrit and Coombs test.,Hepatotoxicity (hepatic necrosis) with fever, jaundice; discontinue if liver abnormalities occur.,Fluid and electrolyte imbalance (hypokalemia, hyponatremia, hypercalcemia) due to thiazide.,May precipitate gout in hyperuricemic patients.,May exacerbate systemic lupus erythematosus.
Concurrent use of other MAOIs or selective serotonin reuptake inhibitors (SSRIs),Pheochromocytoma,Hypersensitivity to sulfonamides (cross-reactivity with thiazide),Anuria
Active hepatic disease (e.g., acute hepatitis, cirrhosis),Prior methyldopa therapy associated with liver disorders,Hypersensitivity to methyldopa or hydrochlorothiazide,Anuria,Sulfonamide allergy (cross-sensitivity with thiazides)
Avoid high-tyramine foods (aged cheese, cured meats, fermented foods) due to potential hypertensive crisis with reserpine; avoid excessive sodium intake; maintain adequate potassium intake; limit alcohol.
Avoid high-sodium foods as they can reduce antihypertensive efficacy. Thiazides may cause hypokalemia; increase dietary potassium (bananas, orange juice) unless contraindicated. Alcohol may enhance orthostatic hypotension.
First trimester: Fetal malformations (neural tube defects, cardiovascular anomalies) due to folate antagonism; contraindicated. Second trimester: Increased risk of growth restriction and oligohydramnios. Third trimester: Neonatal adverse effects including bone marrow suppression and pulmonary hypertension.
First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: Fetal and neonatal adverse effects including oligohydramnios, fetal renal dysfunction, skull ossification delay, and hypotension in the neonate. Avoid use after 20 weeks gestation unless no alternative.
Excreted in breast milk; M/P ratio 0.05-0.2. Contraindicated due to risk of neonatal toxicity (myelosuppression, carcinogenesis).
Methyldopa and hydrochlorothiazide are excreted into human milk. M/P ratio for methyldopa is approximately 0.5-1.0; for hydrochlorothiazide, M/P ratio ~2.0. Methyldopa is considered compatible with breastfeeding. Hydrochlorothiazide may suppress lactation and cause neonatal electrolyte disturbances. Use with caution; monitor infant for signs of diuresis or electrolyte imbalance.
Not applicable; contraindicated in pregnancy. No dose adjustment recommended as use is prohibited. If inadvertent exposure occurs, discontinue immediately.
Pharmacokinetic changes in pregnancy may include increased volume of distribution and enhanced renal clearance. No specific dose adjustment routine is recommended; dosing should be guided by clinical response. Methyldopa starting dose 250 mg twice daily, titrated to effect. Hydrochlorothiazide dose not typically adjusted, but caution due to potential volume depletion.
EUTRON (combination of hydrochlorothiazide and reserpine) is an older antihypertensive. Reserpine depletes catecholamines, requiring weeks for full effect; may cause depression and nasal congestion. Hydrochlorothiazide increases uric acid; monitor gout and hypokalemia. Discontinue 1-2 weeks before electroconvulsive therapy due to interaction with reserpine.
Aldoril 15 (methyldopa 250mg + hydrochlorothiazide 15mg) is rarely used due to superior alternatives. Monitor for hepatotoxicity, hemolytic anemia, and lupus-like syndrome. Titrate slowly to avoid sedation. Contraindicated in active liver disease, pheochromocytoma, and anuria.
Take as prescribed; do not stop suddenly as blood pressure may rise.,May cause dizziness or drowsiness; avoid driving if affected.,Report any mood changes, especially depression or suicidal thoughts.,Possible nasal congestion; use saline spray if needed.,Avoid alcohol as it may enhance side effects.,Use sunscreen; may increase sensitivity to sunlight.,May increase blood sugar; monitor if diabetic.,May cause dry mouth; use sugarless gum or candy.
May cause drowsiness; avoid driving until tolerance develops.,Report unexplained fever, jaundice, or dark urine immediately.,Take at bedtime to minimize sedation.,Avoid sudden discontinuation; follow prescribed tapering schedule.,Use sun protection; thiazides increase photosensitivity.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EUTRON vs ALDORIL 15, answered by our medical review team.
EUTRON is a Antihypertensive that works by EUTRON is a combination of hydrochlorothiazide (thiazide diuretic) and pargyline (monoamine oxidase inhibitor, MAOI). Hydrochlorothiazide inhibits sodium reabsorption in distal convoluted tubule, reducing plasma volume. Pargyline inhibits MAO, increasing catecholamine levels centrally, leading to antihypertensive effect.. ALDORIL 15 is a Antihypertensive Combination that works by Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EUTRON and ALDORIL 15 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EUTRON is: Oral: 5 mg/2.5 mg (amiodipine/valsartan) once daily; maximum dose 10 mg/320 mg once daily.. The standard adult dose of ALDORIL 15 is: 1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EUTRON and ALDORIL 15 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EUTRON is classified as Category C. First trimester: Fetal malformations (neural tube defects, cardiovascular anomalies) due to folate antagonism; contraindicated. Second trimester: Increased risk of growth restricti. ALDORIL 15 is classified as Category C. First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.